Liven Pharma Income Statement

Financials in millions PKR. Fiscal year is July - June.

Millions PKR. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	47.18	127.27	245.09	-	-	-
Revenue Growth (YoY)	-85.87%	-48.07%	-	-	-	-
Cost of Revenue	52.24	111.45	182.96	-	-	-
Gross Profit	-5.06	15.82	62.14	-	-	-
Selling, General & Admin	398.67	389.03	19.14	2.12	2.95	2.1
Other Operating Expenses	109.75	88.84	1.23	-	-	-
Operating Expenses	538.08	507.53	20.37	15.22	17.51	18.19
Operating Income	-543.14	-491.71	41.77	-15.22	-17.51	-18.19
Interest Expense	-1.36	-0.73	-0.02	-	-	-
Interest & Investment Income	0	0.31	-	-	-	-
Other Non Operating Income (Expenses)	-114.1	-0.06	-0	-0	-0	-0
EBT Excluding Unusual Items	-658.59	-492.19	41.74	-15.23	-17.51	-18.19
Pretax Income	-658.59	-492.19	41.74	-15.23	-17.51	-18.19
Income Tax Expense	103.61	92.27	-	-2.9	-3.22	-3.55
Net Income	-762.21	-584.46	41.74	-12.33	-14.29	-14.63
Net Income to Common	-762.21	-584.46	41.74	-12.33	-14.29	-14.63
Shares Outstanding (Basic)	90	70	0	12	12	12
Shares Outstanding (Diluted)	90	70	0	12	12	12
Shares Change (YoY)	-	174375.69%	-99.67%	-	-	-
EPS (Basic)	-8.47	-8.37	1043.60	-1.02	-1.18	-1.21
EPS (Diluted)	-8.47	-8.37	1043.60	-1.02	-1.18	-1.21
Free Cash Flow	-30.13	-24.56	13.8	-2.27	-2.26	-6.79
Free Cash Flow Per Share	-0.34	-0.35	345.08	-0.19	-0.19	-0.56
Gross Margin	-10.72%	12.43%	25.35%	-	-	-
Operating Margin	-1151.13%	-386.34%	17.04%	-	-	-
Profit Margin	-1615.42%	-459.22%	17.03%	-	-	-
Free Cash Flow Margin	-63.87%	-19.30%	5.63%	-	-	-
EBITDA	-516.48	-465.93	64.93	-2.12	-2.95	-2.1
EBITDA Margin	-	-	26.49%	-	-	-
D&A For EBITDA	26.66	25.78	23.16	13.1	14.56	16.08
EBIT	-543.14	-491.71	41.77	-15.22	-17.51	-18.19
EBIT Margin	-	-	17.04%	-	-	-
Advertising Expenses	-	3.26	0.12	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.